CAS Medical Systems (CAS Medical Systems) EBIT : $-4.49 Mil (TTM As of Dec. 2018)

View and export this data going back to 1995. Start your Free Trial

What is CAS Medical Systems EBIT?

CAS Medical Systems's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2018 was $-1.24 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2018 was $-4.49 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. CAS Medical Systems's annualized ROC % for the quarter that ended in Dec. 2018 was -100.62%. CAS Medical Systems's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2018 was -132.18%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. CAS Medical Systems's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2018 was -6.25%.

CAS Medical Systems EBIT Historical Data

The historical data trend for CAS Medical Systems's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CAS Medical Systems EBIT Chart

CAS Medical Systems Annual Data

Trend

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

EBIT

Get a 7-Day Free Trial

-6.82

-6.02

-4.82

-6.39

-4.49

CAS Medical Systems Quarterly Data
	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18
EBIT	Get a 7-Day Free Trial															-1.24	-1.15	-1.13	-0.98	-1.24

Competitive Comparison of CAS Medical Systems's EBIT

For the Medical Instruments & Supplies subindustry, CAS Medical Systems's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CAS Medical Systems's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, CAS Medical Systems's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where CAS Medical Systems's EV-to-EBIT falls into.

CAS Medical Systems EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2018 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.49 Mil.

CAS Medical Systems (NAS:CASM) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

CAS Medical Systems's annualized ROC % for the quarter that ended in Dec. 2018 is calculated as:

	ROC % (Q: Dec. 2018 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Sep. 2018 )	+	Invested Capital (Q: Dec. 2018 ))	/ count )
=	-4.972 * ( 1 - 0% )	/	( (4.902	+	4.981)	/ 2 )
=	-4.972	/	4.9415
=	-100.62 %

where

	Invested Capital		(Q: Sep. 2018 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	11.734	-	2.97	-	( 3.862	-	max(0, 3.038	-	8.948	+	3.862	))
=	4.902

	Invested Capital		(Q: Dec. 2018 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	10.85	-	2.597	-	( 3.272	-	max(0, 3.473	-	8.087	+	3.272	))
=	4.981

Note: The Operating Income data used here is four times the quarterly (Dec. 2018) data.

2. Joel Greenblatt's definition of Return on Capital:

CAS Medical Systems's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2018 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2018 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Sep. 2018		Q: Dec. 2018
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-4.972	/	( ( (1.984 + max(2.116, 0))	+	(1.941 + max(1.482, 0)) )	/	2 )
=	-4.972	/	( ( 4.1	+	3.423 )	/	2 )
=	-4.972	/	3.7615
=	-132.18 %

where Working Capital is:

	Working Capital		(Q: Sep. 2018 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(3.358	+	1.313	+	0.415)	-	(2.97	+	0	+	-4.4408920985006E-16)
=	2.116

	Working Capital		(Q: Dec. 2018 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(3.183	+	1.012	+	0.62)	-	(2.597	+	0	+	0.736)
=	1.482

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2018) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

CAS Medical Systems's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Dec. 2018 )
	=	-4.491	/	71.890
	=	-6.25 %

CAS Medical Systems EBIT Related Terms

Thank you for viewing the detailed overview of CAS Medical Systems's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

CAS Medical Systems (CAS Medical Systems) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » CAS Medical Systems Inc (NAS:CASM) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

44 East Industrial Road, Branford, CT, USA, 06405

Website

http://www.casmed.com

CAS Medical Systems Inc is a medical technology company that develops, manufactures, and markets non-invasive patient monitoring products. The company's products are the FORE-SIGHT and FORE-SIGHT ELITE brand tissue oximeters and sensors. .

Executives

Alan Milinazzo	director	C/O ORTHOFIX INC, 10115 KINCEY AVENUE STE 250, HUNTERSVILLE NC 28078
Thomas M Patton	director, officer: President and CEO	C/O OSTEOTCH INC., 51 JAMES WAY, EATONTOWN NJ 07724
Kenneth R Weisshaar	director	875 PARK AVE APT 2D, NEW YORK NY 10021
James E Thomas	director, 10 percent owner	WOODS END ROAD, NEW CANAAN CT 06840
Thomas, Mcnerney & Partners Ii L.p.	10 percent owner	45 SOUTH 7TH STREET, SUITE 3060, Minneapolis MN 55402
Tmp Associates Ii Lp	10 percent owner	45 SOUTH SEVENTH STREET, SUITE 3060, MINNEAPOLIS MN 55402
Tmp Nominee Ii, Llc	10 percent owner	45 SOUTH SEVENTH STREET, SUITE 3060, MINNEAPOLIS MN 55402
Thomas, Mcnerney & Partners Ii, Llc	10 percent owner	45 SOUTH SEVENTH STREET, SUITE 3060, MINNEAPOLIS MN 55402
Acuta Capital Fund, Lp	10 percent owner	1301 SHOREWAY ROAD, SUITE 350, BELMONT CA 94002
James E Flynn	10 percent owner, other: Possible Member of 10% Group	780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Deerfield Management Company, L.p. (series C)	10 percent owner, other: Possible Member of 10% Group	345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010
Deerfield Mgmt L.p.	10 percent owner, other: Possible Member of 10% Group	780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Deerfield Special Situations Fund, L.p.	10 percent owner, other: Possible Member of 10% Group	780 3RD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Deerfield Special Situations International Master Fund, L.p.	10 percent owner, other: Possible Member of 10% Group	780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Lawrence Burstein	director	C/O UNITY VENTURE CAPITAL ASSOCIATES LTD, 245 FIFTH AVENUE, SUITE 1500, NEW YORK NY 10016